European Nuclear Medicine/Radiopharmaceuticals and Stable Isotopes Market Trends & Forecast to 2017

1
MarketsandMarkets Presents
European Nuclear Medicine/Radiopharmaceuticals
and Stable Isotopes Market Trends Forecast to
2017
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
2
The radioisotope and stable isotope markets have
been segmented according to the type of isotope,
and applications.Both of these markets are broken
down into segments and sub-segments, providing
exhaustive value analysis for the years 2010,
2011, 2012, and forecast to 2017. Each market is
comprehensively analyzed at a granular level by
country (Germany, France, Italy, Spain, U.K.,
Russia, and Rest of Europe) to provide in-depth
information on the European scenario. Browse gtgt
133 data tables
29 figures 292
pages in-depth TOC European Nuclear
Medicine/Radiopharmaceuticals Early buyers will
receive 10 customization of report.
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
3
his report studies the European nuclear medicine
market over the forecast period 2012-2017. The
European radiopharmaceutical market was valued at
1.1 billion in 2012 and is poised to reach 1.6
billion by 2017 at a CAGR of 6.8. The
radioisotopes market is categorized into
diagnostic and therapeutic applications. The
diagnostic market consists of PET and SPECT
technologies, while the therapy market comprises
of beta emitters and brachytherapy seeds. The
SPECT market accounted for a major share of the
diagnostic segment in 2012. Significant
radioisotopes in the SPECT diagnostic market are
Tc-99m, Tl- 201, Ga-67, and I-123, while PET
market is dominated by F-18 and Rb-82. The
therapy market is led by I-131, Sm-153, Re-186,
Y-90, and Lu-177. Alpha emitters are being
developed and considered for cancer treatment,
however not available commercially.
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
4
The stable isotopes market was less than 25
million in 2012 and poised to grow at more than
8.0 CAGR in the next 5 years. Carbon-13
commanded the largest share of the European
stable isotope market in 2012 however deuterium
and oxygen show tremendous potential to grow in
the near future. The market was dominated by two
players, Cambridge Isotope Laboratories (CIL)
(U.S.) and Isotec (Sigma Aldrich) (U.S.) in 2012
jointly contributing more than 50 to the
European stables revenue.
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
5
Contact Us
Mr. RohanNorth - Dominion Plaza, 17304 Preston
Road, Suite 800, Dallas, TX 75252Tel
1-888-6006-441Email sales_at_marketsandmarkets.com
 MarketsandMarkets Bloghttp//twitter.com/market
smarkets
http//www.linkedin.com/company/marketsandmarkets
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html
6
About MarketsandMarkets
MarketsandMarkets is a global market research and
consulting company based in the U.S. We publish
strategically analyzed market research reports
and serve as a business intelligence partner to
Fortune 500 companies across the
world. MarketsandMarkets also provides
multi-client reports, company profiles,
databases, and custom research services. They
cover thirteen industry verticals, including
advanced materials, automotives and
transportation, banking and financial services,
biotechnology, chemicals, consumer goods, energy
and power, food and beverages, industrial
automation, medical devices, pharmaceuticals,
semiconductor and electronics, and
telecommunications and IT. We at
MarketsandMarkets are inspired to help our
clients grow by providing apt business insight
with our huge market intelligence repository.
http//www.marketsandmarkets.com/Market-Reports/eu
ropean-nuclear-medicine-radiopharmaceuticals-marke
t-1107.html